Cargando…
Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods. Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram-positive pathogens, particularly methicillin-r...
Autores principales: | Rubinstein, Ethan, Lalani, Tahaniyat, Corey, G. Ralph, Kanafani, Zeina A., Nannini, Esteban C., Rocha, Marcelo G., Rahav, Galia, Niederman, Michael S., Kollef, Marin H., Shorr, Andrew F., Lee, Patrick C., Lentnek, Arnold L., Luna, Carlos M., Fagon, Jean-Yves, Torres, Antoni, Kitt, Michael M., Genter, Fredric C., Barriere, Steven L., Friedland, H. David, Stryjewski, Martin E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060890/ https://www.ncbi.nlm.nih.gov/pubmed/21148517 http://dx.doi.org/10.1093/cid/ciq031 |
Ejemplares similares
-
Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009) -
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
por: Barriere, Steven L, et al.
Publicado: (2014) -
Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010) -
Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008) -
Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)